| 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: 5,6-dichloro brorphine; SR-14968) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9097 | Aug. 27, 2028 | 21 CFR 1308.11(h)(92) | |
| 1-[1-(2-thienyl)cyclohexyl]pyrrolidine | Schedule I | Hallucinogenic substances | 7473 | | 21 CFR 1308.11(d)(35) | |
| 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one (other names: dipentylone; N,N-dimethylpentylone) | Schedule I | Hallucinogenic substances | 7552 | | 21 CFR 1308.11(d)(105) | |
| 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one (other names: eutylone; bk-EBDB) | Schedule I | Hallucinogenic substances | 7549 | | 21 CFR 1308.11(d)(101) | |
| 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (ethylone) | Schedule I | Hallucinogenic substances | 7547 | | 21 CFR 1308.11(d)(80) | |
| 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone, bk-MBDB) | Schedule I | Hallucinogenic substances | 7541 | | 21 CFR 1308.11(d)(62) | |
| 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone, bk-MBDP) | Schedule I | Hallucinogenic substances | 7542 | | 21 CFR 1308.11(d)(64) | |
| 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (Other names: 4-CN-CUMYL-BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-BINACA; SGT-78) | Schedule I | Hallucinogenic substances | 7089 | | 21 CFR 1308.11(d)(83) | |
| (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (other name: FUB-144) | Schedule I | Hallucinogenic substances | 7014 | | 21 CFR 1308.11(d)(93) | |
| 1-(4-methoxyphenyl)-N-methylpropan-2-amine (other names: para-methoxymethamphetamine, PMMA) | Schedule I | Hallucinogenic substances | 1245 | | 21 CFR 1308.11(d)(88) | |
| [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11) | Schedule I | Hallucinogenic substances | 7011 | | 21 CFR 1308.11(d)(49) | |
| 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201) | Schedule I | Hallucinogenic substances | 7201 | | 21 CFR 1308.11(d)(108) | |
| 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (other names: 5F-CUMYL-PINACA; SGT-25) | Schedule I | Hallucinogenic substances | 7083 | | 21 CFR 1308.11(d)(92) | |
| 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Other name: 5F-CUMYL-P7AICA) | Schedule I | Hallucinogenic substances | 7085 | | 21 CFR 1308.11(d)(85) | |
| 1-androstenediol (3β,17β-dihydroxy-5α-androst-1-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(3) | |
| 1-androstenediol (3α,17β-dihydroxy-5α-androst-1-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(4) | |
| 1-androstenedione (5α-androst-1-en-3,17-dione) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(7) | |
| 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone) | Schedule I | Hallucinogenic substances | 1258 | | 21 CFR 1308.11(d)(67) | |
| 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) | Schedule I | Hallucinogenic substances | 7118 | | 21 CFR 1308.11(d)(107) | |
| 1-phenylcyclohexylamine | Schedule II | Immediate precursors | 7460 | | 21 CFR 1308.12(g)(2)(i) | |
| 1-piperidinocyclohexanecarbonitrile (PCC) | Schedule II | Immediate precursors | 8603 | | 21 CFR 1308.12(g)(2)(ii) | |
| 2-(2-((2,3-dihydrobenzofuran-5-yl)methyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Ethyleneoxynitazene) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9770 | Oct. 15, 2027 | 21 CFR 1308.11(h)(79) | |
| 2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine (Other names: etodesnitazene; etazene) | Schedule I | Opiates | 9765 | | 21 CFR 1308.11(b)(42) | |
| 2-(2-(4-ethoxybenzyl)-5-methyl-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: 5-methyl etodesnitazene) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9767 | Oct. 15, 2027 | 21 CFR 1308.11(h)(81) | |
| 2-(2-(4-ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N-ethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: N-desethyl etonitazene) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9768 | Oct. 15, 2027 | 21 CFR 1308.11(h)(82) | |
| 2-(2-(4-ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-dimethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: N,N-dimethylamino etonitazene) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9771 | Oct. 15, 2027 | 21 CFR 1308.11(h)(84) | |
| 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) | Schedule I | Hallucinogenic substances | 7509 | | 21 CFR 1308.11(d)(38) | |
| 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) | Schedule I | Hallucinogenic substances | 7508 | | 21 CFR 1308.11(d)(39) | |
| 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) | Schedule I | Hallucinogenic substances | 7524 | | 21 CFR 1308.11(d)(46) | |
| 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) | Schedule I | Hallucinogenic substances | 7521 | | 21 CFR 1308.11(d)(45) | |
| 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) | Schedule I | Hallucinogenic substances | 7517 | | 21 CFR 1308.11(d)(44) | |
| 2-(2-(benzodioxol-5-ylmethyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: Methylenedioxynitazene; 3′,4′-methylenedioxynitazene) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9766 | Oct. 15, 2027 | 21 CFR 1308.11(h)(80) | |
| 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(29) | |
| 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe, 2C-B-NBOMe) | Schedule I | Hallucinogenic substances | 7536 | | 21 CFR 1308.11(d)(57) | |
| 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) | Schedule I | Hallucinogenic substances | 7519 | | 21 CFR 1308.11(d)(40) | |
| 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe, 2C-C-NBOMe) | Schedule I | Hallucinogenic substances | 7537 | | 21 CFR 1308.11(d)(56) | |
| 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (Other names: N-pyrrolidino etonitazene; etonitazepyne) | Schedule I | Opiates | 9758 | | 21 CFR 1308.11(b)(78) | |
| 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) | Schedule I | Hallucinogenic substances | 7385 | | 21 CFR 1308.11(d)(42) | |
| 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) | Schedule I | Hallucinogenic substances | 7518 | | 21 CFR 1308.11(d)(41) | |
| 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe, 2C-I-NBOMe) | Schedule I | Hallucinogenic substances | 7538 | | 21 CFR 1308.11(d)(55) | |
| 2-(4-isopropoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: N-pyrrolidino isotonitazene) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9772 | Oct. 15, 2027 | 21 CFR 1308.11(h)(85) | |
| 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) | Schedule I | Hallucinogenic substances | 7532 | | 21 CFR 1308.11(d)(43) | |
| 2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (Other names: N-pyrrolidino metonitazene; metonitazepyne) | Schedule I | Opiates | 9762 | | 21 CFR 1308.11(b)(79) | |
| 2,5-dimethoxy-4-ethylamphet-amine | Schedule I | Hallucinogenic substances | 7399 | | 21 CFR 1308.11(d)(5) | |
| 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7) | Schedule I | Hallucinogenic substances | 7348 | | 21 CFR 1308.11(d)(6) | |
| 2,5-dimethoxyamphetamine | Schedule I | Hallucinogenic substances | 7396 | | 21 CFR 1308.11(d)(4) | |
| 2′,5′-Dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide) | Schedule I | Opiates | 9861 | | 21 CFR 1308.11(b)(37) | |
| 2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(27) | |
| 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol) | Schedule IV | Narcotic drugs | 9752 | | 21 CFR 1308.14(b)(3) | |
| 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine, MXE) | Schedule I | Hallucinogenic substances | 7286 | | 21 CFR 1308.11(d)(100) | |
| 2′-Fluoro ortho-fluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide; also known as 2′-fluoro 2-fluorofentanyl) | Schedule I | Opiates | 9855 | | 21 CFR 1308.11(b)(48) | |
| 2-Fluorodeschloroketamine, its salts, isomers, and salts of isomers (other name: 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one; also known as 2-FDCK) | Schedule I | Temporary listing of substances subject to emergency scheduling | 7284 | May 22, 2028 | 21 CFR 1308.11(h)(87) | |
| 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one) | Schedule I | Opiates | 9664 | | 21 CFR 1308.11(b)(64) | |
| 2-(methylamino)-1-(3-methylphenyl)propan-1-one (other names: 3-MMC; 3-methylmethcathinone) | Schedule I | Hallucinogenic substances | 1259 | | 21 CFR 1308.11(d)(104) | |
| 2-(methylamino)-1-phenylpentan-1-one (pentedrone) | Schedule I | Hallucinogenic substances | 1246 | | 21 CFR 1308.11(d)(63) | |
| 3-(3-(1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propanenitrile, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: N-propionitrile chlorphine; cychlorphine) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9094 | Aug. 27, 2028 | 21 CFR 1308.11(h)(94) | |
| 3,4,5-trimethoxy amphetamine | Schedule I | Hallucinogenic substances | 7390 | | 21 CFR 1308.11(d)(14) | |
| 3,4-methylenedioxy amphetamine | Schedule I | Hallucinogenic substances | 7400 | | 21 CFR 1308.11(d)(10) | |
| 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)-phenethylamine, N-ethyl MDA, MDE, MDEA | Schedule I | Hallucinogenic substances | 7404 | | 21 CFR 1308.11(d)(12) | |
| 3,4-Methylenedioxy-N-methylcathinone (Methylone) | Schedule I | Hallucinogenic substances | 7540 | | 21 CFR 1308.11(d)(47) | |
| 3,4-methylenedioxymethamphetamine (MDMA) | Schedule I | Hallucinogenic substances | 7405 | | 21 CFR 1308.11(d)(11) | |
| 3,4-methylenedioxypyrovalerone (MDPV) | Schedule I | Hallucinogenic substances | 7535 | | 21 CFR 1308.11(d)(37) | |
| 3β,17β-dihydroxy-5α-androstane | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(25) | |
| 3α,17β-dihydroxy-5α-androstane | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(26) | |
| 3-fluoro-N-methylcathinone (3-FMC) | Schedule I | Hallucinogenic substances | 1233 | | 21 CFR 1308.11(d)(66) | |
| 3-Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide) | Schedule I | Opiates | 9860 | | 21 CFR 1308.11(b)(50) | |
| 3β-hydroxy-estra-4,9,11-trien-17-one | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(42) | |
| 3-methoxyphencyclidine (Other names: 1-(1-(3-methoxyphenyl)cyclohexyl)piperidine; 3-MeO-PCP) | Schedule I | Hallucinogenic substances | 7457 | | 21 CFR 1308.11(d)(109) | |
| 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide) | Schedule I | Opiates | 9813 | | 21 CFR 1308.11(b)(65) | |
| 3-Methylthiofentanyl (N-[3-methyl-1-(2-thienylethyl)-4-piperidinyl]-N-phenylpropanamide) | Schedule I | Opiates | 9833 | | 21 CFR 1308.11(b)(66) | |
| 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine) | Schedule I | Stimulants | 1595 | | 21 CFR 1308.11(f)(5) | |
| 4-androstenediol (3β,17β-dihydroxy-androst-4-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(5) | |
| 4-androstenedione (androst-4-en-3,17-dione) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(8) | |
| 4-anilino-N-phenethylpiperidine (ANPP) | Schedule II | Immediate precursors | 8333 | | 21 CFR 1308.12(g)(3)(i) | |
| 4-bromo-2,5-dimethoxy-amphetamine | Schedule I | Hallucinogenic substances | 7391 | | 21 CFR 1308.11(d)(2) | |
| 4-Bromo-2,5-dimethoxyphenethylamine | Schedule I | Hallucinogenic substances | 7392 | | 21 CFR 1308.11(d)(3) | |
| 4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(18) | |
| 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(19) | |
| 4-chloro-17α-methyl-androst-4-ene-3β,17β-diol | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(17) | |
| 4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(16) | |
| 4′-Chloro-alpha-pyrrolidinovalerophenone (Other names: 4-chloro-α-PVP; 4′-chloro-α-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one) | Schedule I | Hallucinogenic substances | 7443 | | 21 CFR 1308.11(d)(99) | |
| 4-Chloromethcathinone (4-CMC, 1-(4-chlorophenyl)-2-(methylamino)propan-1-one) | Schedule I | Hallucinogenic substances | 1239 | | 21 CFR 1308.11(d)(106) | |
| 4-dihydrotestosterone (17β-hydroxy-androstan-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(23) | |
| 4-fluoro-N-methylcathinone (4-FMC; flephedrone) | Schedule I | Hallucinogenic substances | 1238 | | 21 CFR 1308.11(d)(65) | |
| 4-Fluoroamphetamine (4-FA, 1-(4-fluorophenyl)propan-2-amine, para-fluoroamphetamine) | Schedule I | Stimulants | 1476 | | 21 CFR 1308.11(f)(8) | |
| 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide; also known as para-fluoroisobutyryl fentanyl) | Schedule I | Opiates | 9824 | | 21 CFR 1308.11(b)(47) | |
| 4-hydroxy-19-nortestosterone (4,17β-dihydroxy-estr-4-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(38) | |
| 4-hydroxy-androst-4-ene-3,17-dione | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(39) | |
| 4-hydroxytestosterone (4,17β-dihydroxy-androst-4-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(43) | |
| 4-methoxyamphetamine | Schedule I | Hallucinogenic substances | 7411 | | 21 CFR 1308.11(d)(7) | |
| 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (other names: α-PiHP; alpha-PiHP) | Schedule I | Hallucinogenic substances | 7551 | | 21 CFR 1308.11(d)(103) | |
| 4-methyl-2,5-dimethoxy-amphetamine | Schedule I | Hallucinogenic substances | 7395 | | 21 CFR 1308.11(d)(9) | |
| 4′-Methyl acetyl fentanyl (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide) | Schedule I | Opiates | 9819 | | 21 CFR 1308.11(b)(63) | |
| 4-Methyl-alpha-ethylaminopentiophenone (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one) | Schedule I | Hallucinogenic substances | 7245 | | 21 CFR 1308.11(d)(96) | |
| 4′-Methyl-alpha-pyrrolidinohexiophenone (Other names: MPHP; 4′-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one) | Schedule I | Hallucinogenic substances | 7446 | | 21 CFR 1308.11(d)(97) | |
| 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP) | Schedule I | Hallucinogenic substances | 7498 | | 21 CFR 1308.11(d)(60) | |
| 4-methyl-N-ethylcathinone (4-MEC) | Schedule I | Hallucinogenic substances | 1249 | | 21 CFR 1308.11(d)(59) | |
| 4-methylmethcathinone (Mephedrone) | Schedule I | Hallucinogenic substances | 1248 | | 21 CFR 1308.11(d)(36) | |
| 5,6-dichloro-1-(1-(4-chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: 5,6-dichloro desmethylchlorphine; SR-17018) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9096 | Aug. 27, 2028 | 21 CFR 1308.11(h)(93) | |
| 5α-androstan-3,6,17-trione | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(2) | |
| 5α-androstan-3,17-dione | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(1) | |
| 5-androstenediol (3β,17β-dihydroxy-androst-5-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(6) | |
| 5-androstenedione (androst-5-en-3,17-dione) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(9) | |
| 5-methoxy-3,4-methylenedioxy-amphetamine | Schedule I | Hallucinogenic substances | 7401 | | 21 CFR 1308.11(d)(8) | |
| 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT) | Schedule I | Hallucinogenic substances | 7439 | | 21 CFR 1308.11(d)(20) | |
| 5-methoxy-N,N-dimethyltryptamine Some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT | Schedule I | Hallucinogenic substances | 7431 | | 21 CFR 1308.11(d)(15) | |
| 5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (other names: N-pyrrolidino protonitazene; protonitazepyne) | Schedule I | Opiates | 9763 | | 21 CFR 1308.11(b)(80) | |
| 5-Pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-one (other names: CUMYL-PEGACLONE; SGT-151) | Schedule I | Hallucinogenic substances | 7093 | | 21 CFR 1308.11(d)(116) | |
| 6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol (other names: hexahydrocannabinol, HHC) | Schedule I | Hallucinogenic substances | 7220 | | 21 CFR 1308.11(d)(115) | |
| 6-bromo-androsta-1,4-diene-3,17-dione | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(13) | |
| 6-bromo-androstan-3,17-dione | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(14) | |
| 6α-methyl-androst-4-ene-3,17-dione | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(53) | |
| 8-(1-(4-chlorophenyl)ethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: spirochlorphine; R-6890) | Schedule I | Temporary listing of substances subject to emergency scheduling | 9093 | Aug. 27, 2028 | 21 CFR 1308.11(h)(95) | |
| 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine, its salts, isomers, and salts of isomers (Other name: bromazolam) | Schedule I | Temporary listing of substances subject to emergency scheduling | 2778 | Mar. 16, 2028 | 21 CFR 1308.11(h)(86) | |
| 13β-ethyl-17β-hydroxygon-4-en-3-one | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(31) | |
| 17β-hydroxy-androstano[2,3-d]isoxazole | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(40) | |
| 17β-hydroxy-androstano[3,2-c]isoxazole | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(41) | |
| 17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (a.k.a. “17-α-methyl-1-testosterone”) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(60) | |
| 17α-methyl-3β,17β-dihydroxy-5α-androstane | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(55) | |
| 17α-methyl-3α,17β-dihydroxy-5α-androstane | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(56) | |
| 17α-methyl-3β,17β-dihydroxyandrost-4-ene | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(57) | |
| 17α-methyl-4-hydroxynandrolone (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(58) | |
| 17α-methyl-5α-androstan-17β-ol | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(51) | |
| 17α-methyl-androst-2-ene-3,17β-diol | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(54) | |
| 17α-methyl-androsta-1,4-diene-3,17β-diol | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(50) | |
| 17α-methyl-androstan-3-hydroxyimine-17β-ol | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(52) | |
| 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(37) | |
| 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(69) | |
| 19-nor-4-androstenediol (3β,17β-dihydroxyestr-4-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(65) | |
| 19-nor-4-androstenediol (3α,17β-dihydroxyestr-4-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(66) | |
| 19-nor-4-androstenedione (estr-4-en-3,17-dione) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(70) | |
| 19-nor-5-androstenediol (3β,17β-dihydroxyestr-5-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(67) | |
| 19-nor-5-androstenediol (3α,17β-dihydroxyestr-5-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(68) | |
| 19-nor-5-androstenedione (estr-5-en-3,17-dione) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(71) | |
| [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201) | Schedule I | Hallucinogenic substances | 7024 | | 21 CFR 1308.11(d)(71) | |
| Δ1-dihydrotestosterone (a.k.a. “1-testosterone”) (17β-hydroxy-5α-androst-1-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(24) | |
| (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) | Schedule I | Hallucinogenic substances | 7144 | | 21 CFR 1308.11(d)(48) | |
| [3,2-c]furazan-5α-androstan-17β-ol | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(36) | |
| [3,2-c]pyrazole-androst-4-en-17β-ol | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(80) | |
| Acetorphine | Schedule I | Opium derivatives | 9319 | | 21 CFR 1308.11(c)(1) | |
| Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide) | Schedule I | Opiates | 9815 | | 21 CFR 1308.11(b)(1) | |
| Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) | Schedule I | Opiates | 9821 | | 21 CFR 1308.11(b)(3) | |
| Acetyldihydrocodeine | Schedule I | Opium derivatives | 9051 | | 21 CFR 1308.11(c)(2) | |
| Acetylmethadol | Schedule I | Opiates | 9601 | | 21 CFR 1308.11(b)(2) | |
| Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; also known as acryloylfentanyl) | Schedule I | Opiates | 9811 | | 21 CFR 1308.11(b)(4) | |
| AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) | Schedule I | Opiates | 9551 | | 21 CFR 1308.11(b)(5) | |
| Alfaxalone | Schedule IV | Depressants | 2731 | | 21 CFR 1308.14(c)(1) | |
| Alfentanil | Schedule II | Opiates | 9737 | | 21 CFR 1308.12(c)(1) | |
| Allylprodine | Schedule I | Opiates | 9602 | | 21 CFR 1308.11(b)(6) | |
| Alpha-ethyltryptamine | Schedule I | Hallucinogenic substances | 7249 | | 21 CFR 1308.11(d)(1) | |
| alpha′-Methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) | Schedule I | Opiates | 9864 | | 21 CFR 1308.11(b)(10) | |
| alpha-Methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine) | Schedule I | Opiates | 9814 | | 21 CFR 1308.11(b)(11) | |
| alpha-Methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) | Schedule I | Opiates | 9832 | | 21 CFR 1308.11(b)(12) | |
| Alpha-methyltryptamine (other name: AMT) | Schedule I | Hallucinogenic substances | 7432 | | 21 CFR 1308.11(d)(16) | |
| alpha-pyrrolidinobutiophenone (α-PBP) | Schedule I | Hallucinogenic substances | 7546 | | 21 CFR 1308.11(d)(68) | |
| alpha-Pyrrolidinoheptaphenone (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one) | Schedule I | Hallucinogenic substances | 7548 | | 21 CFR 1308.11(d)(98) | |
| alpha-Pyrrolidinohexanophenone (Other names: α-PHP; α-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one) | Schedule I | Hallucinogenic substances | 7544 | | 21 CFR 1308.11(d)(95) | |
| alpha-pyrrolidinopentiophenone (α-PVP) | Schedule I | Hallucinogenic substances | 7545 | | 21 CFR 1308.11(d)(61) | |
| Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM) | Schedule I | Opiates | 9603 | | 21 CFR 1308.11(b)(7) | |
| Alphameprodine | Schedule I | Opiates | 9604 | | 21 CFR 1308.11(b)(8) | |
| Alphamethadol | Schedule I | Opiates | 9605 | | 21 CFR 1308.11(b)(9) | |
| Alphaprodine | Schedule II | Opiates | 9010 | | 21 CFR 1308.12(c)(2) | |
| Alprazolam | Schedule IV | Depressants | 2882 | | 21 CFR 1308.14(c)(2) | |
| Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid) | Schedule I | Stimulants | 1219 | | 21 CFR 1308.11(f)(1) | |
| Aminorex (Some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-phenly-2-oxazolamine) | Schedule I | Stimulants | 1585 | | 21 CFR 1308.11(f)(2) | |
| Amobarbital | Schedule II | Depressants | 2125 | | 21 CFR 1308.12(e)(1) | |
| Amobarbital | Schedule III | Depressants | 2126 | | 21 CFR 1308.13(c)(1)(i) | Any compound, mixture or preparation containing |
| Amobarbital | Schedule III | Depressants | 2126 | | 21 CFR 1308.13(c)(2)(i) | Any suppository dosage form containing |
| Amphetamine, its salts, optical isomers, and salts of its optical isomers | Schedule II | Stimulants | 1100 | | 21 CFR 1308.12(d)(1) | |
| Anileridine | Schedule II | Opiates | 9020 | | 21 CFR 1308.12(c)(3) | |
| Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act | Schedule III | Depressants | 2012 | | 21 CFR 1308.13(c)(6) | |
| Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (b) (1) of this section, except that these substances shall not include the isoquinoline alkaloids of opium | Schedule II | Substances, vegetable origin or chemical synthesis | | | 21 CFR 1308.12(b)(2) | |
| Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof | Schedule III | Depressants | 2100 | | 21 CFR 1308.13(c)(3) | |
| Barbital | Schedule IV | Depressants | 2145 | | 21 CFR 1308.14(c)(3) | |
| Benzethidine | Schedule I | Opiates | 9606 | | 21 CFR 1308.11(b)(13) | |
| Benzphetamine | Schedule III | Stimulants | 1228 | | 21 CFR 1308.13(b)(2) | |
| Benzylmorphine | Schedule I | Opium derivatives | 9052 | | 21 CFR 1308.11(c)(3) | |
| beta-Hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide) | Schedule I | Opiates | 9831 | | 21 CFR 1308.11(b)(16) | |
| beta-Hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide) | Schedule I | Opiates | 9830 | | 21 CFR 1308.11(b)(15) | |
| beta-Hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide) | Schedule I | Opiates | 9836 | | 21 CFR 1308.11(b)(17) | |
| beta-Methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide; also known as β-methyl fentanyl) | Schedule I | Opiates | 9856 | | 21 CFR 1308.11(b)(20) | |
| beta-methylacetyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)acetamide) | Schedule I | Opiates | 9868 | | 21 CFR 1308.11(b)(21) | |
| beta′-Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide; also known as β′-phenyl fentanyl; 3-phenylpropanoyl fentanyl) | Schedule I | Opiates | 9842 | | 21 CFR 1308.11(b)(22) | |
| Betacetylmethadol | Schedule I | Opiates | 9607 | | 21 CFR 1308.11(b)(14) | |
| Betameprodine | Schedule I | Opiates | 9608 | | 21 CFR 1308.11(b)(18) | |
| Betamethadol | Schedule I | Opiates | 9609 | | 21 CFR 1308.11(b)(19) | |
| Betaprodine | Schedule I | Opiates | 9611 | | 21 CFR 1308.11(b)(23) | |
| Bezitramide | Schedule II | Opiates | 9800 | | 21 CFR 1308.12(c)(4) | |
| bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(10) | |
| boldenone (17β-hydroxyandrost-1,4-diene-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(11) | |
| boldione (androsta-1,4-diene-3,17-dione) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(12) | |
| Brexanolone | Schedule IV | Depressants | 2400 | | 21 CFR 1308.14(c)(4) | |
| Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) | Schedule V | Depressants | 2710 | | 21 CFR 1308.15(e)(1) | |
| Bromazepam | Schedule IV | Depressants | 2748 | | 21 CFR 1308.14(c)(5) | |
| brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one) | Schedule I | Opiates | 9098 | | 21 CFR 1308.11(b)(24) | |
| Bufotenine | Schedule I | Hallucinogenic substances | 7433 | | 21 CFR 1308.11(d)(17) | |
| Bulk dextropropoxyphene (non-dosage forms) | Schedule II | Opiates | 9273 | | 21 CFR 1308.12(c)(5) | |
| Buprenorphine | Schedule III | Narcotic drugs | 9064 | | 21 CFR 1308.13(e)(2)(i) | |
| Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) | Schedule I | Opiates | 9751 | | 21 CFR 1308.11(b)(25) | |
| Butorphanol (including its optical isomers) | Schedule IV | Other substances | 9720 | | 21 CFR 1308.14(g)(2) | |
| Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide) | Schedule I | Opiates | 9822 | | 21 CFR 1308.11(b)(26) | |
| calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(15) | |
| Camazepam | Schedule IV | Depressants | 2749 | | 21 CFR 1308.14(c)(6) | |
| Cannabimimetic agents | Schedule I | Cannabimimetic agents | 7000 | | 21 CFR 1308.11(g)(1) | |
| Carfentanil | Schedule II | Opiates | 9743 | | 21 CFR 1308.12(c)(6) | |
| Carisoprodol | Schedule IV | Depressants | 8192 | | 21 CFR 1308.14(c)(7) | |
| Cathine ((+)-norpseudoephedrine) | Schedule IV | Stimulants | 1230 | | 21 CFR 1308.14(f)(1) | |
| Cathinone | Schedule I | Stimulants | 1235 | | 21 CFR 1308.11(f)(4) | |
| Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester) | Schedule V | Depressants | 2720 | | 21 CFR 1308.15(e)(2) | |
| Chloral betaine | Schedule IV | Depressants | 2460 | | 21 CFR 1308.14(c)(8) | |
| Chloral hydrate | Schedule IV | Depressants | 2465 | | 21 CFR 1308.14(c)(9) | |
| Chlordiazepoxide | Schedule IV | Depressants | 2744 | | 21 CFR 1308.14(c)(10) | |
| Chlorhexadol | Schedule III | Depressants | 2510 | | 21 CFR 1308.13(c)(4) | |
| Chlorphentermine | Schedule III | Stimulants | 1645 | | 21 CFR 1308.13(b)(3) | |
| Cipepofol | Schedule IV | Depressants | 2139 | | 21 CFR 1308.14(c)(11) | |
| (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine) | Schedule I | Stimulants | 1590 | | 21 CFR 1308.11(f)(12) | |
| Clobazam | Schedule IV | Depressants | 2751 | | 21 CFR 1308.14(c)(12) | |
| Clonazepam | Schedule IV | Depressants | 2737 | | 21 CFR 1308.14(c)(13) | |
| Clonazolam (Other name: 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) | Schedule I | Depressants | 2786 | | 21 CFR 1308.11(e)(1) | |
| Clonitazene | Schedule I | Opiates | 9612 | | 21 CFR 1308.11(b)(27) | |
| Clorazepate | Schedule IV | Depressants | 2768 | | 21 CFR 1308.14(c)(14) | |
| Clortermine | Schedule III | Stimulants | 1647 | | 21 CFR 1308.13(b)(4) | |
| clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(20) | |
| Clotiazepam | Schedule IV | Depressants | 2752 | | 21 CFR 1308.14(c)(15) | |
| Cloxazolam | Schedule IV | Depressants | 2753 | | 21 CFR 1308.14(c)(16) | |
| Coca leaves | Schedule II | Substances, vegetable origin or chemical synthesis | 9040 | | 21 CFR 1308.12(b)(4) | |
| cocaine | Schedule II | Substances, vegetable origin or chemical synthesis | 9041 | | 21 CFR 1308.12(b)(4) | |
| Codeine | Schedule II | Substances, vegetable origin or chemical synthesis | 9050 | | 21 CFR 1308.12(b)(1)(i) | |
| codeine | Schedule III | Narcotic drugs | 9803 | | 21 CFR 1308.13(e)(1)(i) | Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium |
| codeine | Schedule III | Narcotic drugs | 9804 | | 21 CFR 1308.13(e)(1)(ii) | Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
| codeine | Schedule V | Narcotic drugs containing non-narcotic active medicinal ingredients | | | 21 CFR 1308.15(c)(1) | Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams |
| Codeine methylbromide | Schedule I | Opium derivatives | 9070 | | 21 CFR 1308.11(c)(4) | |
| Codeine-N-Oxide | Schedule I | Opium derivatives | 9053 | | 21 CFR 1308.11(c)(5) | |
| Concentrate of poppy straw | Schedule II | Substances, vegetable origin or chemical synthesis | 9670 | | 21 CFR 1308.12(b)(5) | |
| Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide) | Schedule I | Opiates | 9844 | | 21 CFR 1308.11(b)(28) | |
| Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide) | Schedule I | Opiates | 9847 | | 21 CFR 1308.11(b)(29) | |
| Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide) | Schedule I | Opiates | 9845 | | 21 CFR 1308.11(b)(30) | |
| Cyprenorphine | Schedule I | Opium derivatives | 9054 | | 21 CFR 1308.11(c)(6) | |
| Daridorexant | Schedule IV | Depressants | 2410 | | 21 CFR 1308.14(c)(17) | |
| dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(21) | |
| Delorazepam | Schedule IV | Depressants | 2754 | | 21 CFR 1308.14(c)(18) | |
| Desomorphine | Schedule I | Opium derivatives | 9055 | | 21 CFR 1308.11(c)(7) | |
| desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol) (a.k.a. “madol”) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(22) | |
| Dextromoramide | Schedule I | Opiates | 9613 | | 21 CFR 1308.11(b)(31) | |
| Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane) | Schedule IV | Narcotic drugs | 9278 | | 21 CFR 1308.14(b)(2) | |
| Diampromide | Schedule I | Opiates | 9615 | | 21 CFR 1308.11(b)(32) | |
| Diazepam | Schedule IV | Depressants | 2765 | | 21 CFR 1308.14(c)(19) | |
| Dichloralphenazone | Schedule IV | Depressants | 2467 | | 21 CFR 1308.14(c)(20) | |
| Diclazepam (Other name: 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one) | Schedule I | Depressants | 2789 | | 21 CFR 1308.11(e)(2) | |
| Diethylpropion | Schedule IV | Stimulants | 1610 | | 21 CFR 1308.14(f)(2) | |
| Diethylthiambutene | Schedule I | Opiates | 9616 | | 21 CFR 1308.11(b)(33) | |
| Diethyltryptamine | Schedule I | Hallucinogenic substances | 7434 | | 21 CFR 1308.11(d)(18) | |
| Difenoxin | Schedule I | Opiates | 9168 | | 21 CFR 1308.11(b)(34) | |
| difenoxin | Schedule V | Narcotic drugs containing non-narcotic active medicinal ingredients | | | 21 CFR 1308.15(c)(6) | Not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit |
| Dihydrocodeine | Schedule II | Opiates | 9120 | | 21 CFR 1308.12(c)(7) | |
| dihydrocodeine | Schedule III | Narcotic drugs | 9807 | | 21 CFR 1308.13(e)(1)(iii) | Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts |
| dihydrocodeine | Schedule V | Narcotic drugs containing non-narcotic active medicinal ingredients | | | 21 CFR 1308.15(c)(2) | Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams |
| Dihydroetorphine | Schedule II | Substances, vegetable origin or chemical synthesis | 9334 | | 21 CFR 1308.12(b)(1)(ii) | |
| Dihydromorphine | Schedule I | Opium derivatives | 9145 | | 21 CFR 1308.11(c)(8) | |
| Dimenoxadol | Schedule I | Opiates | 9617 | | 21 CFR 1308.11(b)(35) | |
| Dimepheptanol | Schedule I | Opiates | 9618 | | 21 CFR 1308.11(b)(36) | |
| Dimethylthiambutene | Schedule I | Opiates | 9619 | | 21 CFR 1308.11(b)(38) | |
| Dimethyltryptamine | Schedule I | Hallucinogenic substances | 7435 | | 21 CFR 1308.11(d)(19) | |
| Dioxaphetyl butyrate | Schedule I | Opiates | 9621 | | 21 CFR 1308.11(b)(39) | |
| Diphenoxylate | Schedule II | Opiates | 9170 | | 21 CFR 1308.12(c)(8) | |
| diphenoxylate | Schedule V | Narcotic drugs containing non-narcotic active medicinal ingredients | | | 21 CFR 1308.15(c)(4) | Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit |
| Dipipanone | Schedule I | Opiates | 9622 | | 21 CFR 1308.11(b)(40) | |
| Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] | Schedule II | Hallucinogenic substances | 7365 | | 21 CFR 1308.12(f)(2) | in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration |
| Dronabinol (synthetic) | Schedule III | Hallucinogenic substances | 7369 | | 21 CFR 1308.13(g)(1) | in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved product |
| drostanolone (17β-hydroxy-2α-methyl-5α-androstan-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(28) | |
| Drotebanol | Schedule I | Opium derivatives | 9335 | | 21 CFR 1308.11(c)(9) | |
| ecgonine | Schedule II | Substances, vegetable origin or chemical synthesis | 9180 | | 21 CFR 1308.12(b)(4) | |
| Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers | Schedule IV | Other substances | 9725 | | 21 CFR 1308.14(g)(3) | |
| Embutramide | Schedule III | Depressants | 2020 | | 21 CFR 1308.13(c)(5) | |
| Estazolam | Schedule IV | Depressants | 2756 | | 21 CFR 1308.14(c)(21) | |
| estra-4,9,11-triene-3,17-dione | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(30) | |
| Ethchlorvynol | Schedule IV | Depressants | 2540 | | 21 CFR 1308.14(c)(22) | |
| Ethinamate | Schedule IV | Depressants | 2545 | | 21 CFR 1308.14(c)(23) | |
| ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (other name: 5F-EDMB-PINACA) | Schedule I | Hallucinogenic substances | 7036 | | 21 CFR 1308.11(d)(89) | |
| Ethyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (other names: 5F-EDMB-PICA; 5F-EDMB-2201) | Schedule I | Hallucinogenic substances | 7094 | | 21 CFR 1308.11(d)(113) | |
| Ethyl loflazepate | Schedule IV | Depressants | 2758 | | 21 CFR 1308.14(c)(24) | |
| Ethylamine analog of phencyclidine | Schedule I | Hallucinogenic substances | 7455 | | 21 CFR 1308.11(d)(32) | |
| ethylestrenol (17α-ethyl-17β-hydroxyestr-4-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(32) | |
| Ethylmethylthiambutene | Schedule I | Opiates | 9623 | | 21 CFR 1308.11(b)(41) | |
| Ethylmorphine | Schedule II | Substances, vegetable origin or chemical synthesis | 9190 | | 21 CFR 1308.12(b)(1)(iii) | |
| ethylmorphine | Schedule III | Narcotic drugs | 9808 | | 21 CFR 1308.13(e)(1)(iv) | Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
| ethylmorphine | Schedule V | Narcotic drugs containing non-narcotic active medicinal ingredients | | | 21 CFR 1308.15(c)(3) | Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams |
| Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate) | Schedule I | Stimulants | 1727 | | 21 CFR 1308.11(f)(6) | |
| Etizolam (Other name: 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine) | Schedule I | Depressants | 2780 | | 21 CFR 1308.11(e)(3) | |
| Etonitazene | Schedule I | Opiates | 9624 | | 21 CFR 1308.11(b)(43) | |
| Etorphine (except hydrochloride salt) | Schedule I | Opium derivatives | 9056 | | 21 CFR 1308.11(c)(10) | |
| Etorphine hydrochloride | Schedule II | Substances, vegetable origin or chemical synthesis | 9059 | | 21 CFR 1308.12(b)(1)(iv) | |
| Etoxeridine | Schedule I | Opiates | 9625 | | 21 CFR 1308.11(b)(44) | |
| Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester] | Schedule V | Depressants | 2779 | | 21 CFR 1308.15(e)(3) | |
| Fencamfamin | Schedule IV | Stimulants | 1760 | | 21 CFR 1308.14(f)(3) | |
| Fenethylline | Schedule I | Stimulants | 1503 | | 21 CFR 1308.11(f)(7) | |
| Fenproporex | Schedule IV | Stimulants | 1575 | | 21 CFR 1308.14(f)(4) | |
| Fentanyl | Schedule II | Opiates | 9801 | | 21 CFR 1308.12(c)(9) | |
| Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate) | Schedule I | Opiates | 9851 | | 21 CFR 1308.11(b)(45) | |
| Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers | Schedule I | Temporary listing of substances subject to emergency scheduling | 9850 | | 21 CFR 1308.11(h)(30) | |
| Flualprazolam (Other name: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) | Schedule I | Depressants | 2785 | | 21 CFR 1308.11(e)(4) | |
| Flubromazolam (Other name: 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) | Schedule I | Depressants | 2788 | | 21 CFR 1308.11(e)(5) | |
| Fludiazepam | Schedule IV | Depressants | 2759 | | 21 CFR 1308.14(c)(25) | |
| Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine) | Schedule I | Opiates | 9756 | | 21 CFR 1308.11(b)(46) | |
| Flunitrazepam | Schedule IV | Depressants | 2763 | | 21 CFR 1308.14(c)(26) | |
| fluoxymesterone (9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(33) | |
| Flurazepam | Schedule IV | Depressants | 2767 | | 21 CFR 1308.14(c)(27) | |
| formebolone (2-formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(34) | |
| Fospropofol | Schedule IV | Depressants | 2138 | | 21 CFR 1308.14(c)(28) | |
| Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide) | Schedule I | Opiates | 9834 | | 21 CFR 1308.11(b)(49) | |
| furazabol (17α-methyl-17β-hydroxyandrostano[2,3-c]furazan) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(35) | |
| Furethidine | Schedule I | Opiates | 9626 | | 21 CFR 1308.11(b)(51) | |
| gamma-hydroxybutyric acid (some other names include GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate) | Schedule I | Depressants | 2010 | | 21 CFR 1308.11(e)(6) | |
| Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one) | Schedule V | Depressants | 2401 | | 21 CFR 1308.15(e)(4) | |
| Glutethimide | Schedule II | Depressants | 2550 | | 21 CFR 1308.12(e)(2) | |
| Granulated opium | Schedule II | Substances, vegetable origin or chemical synthesis | 9640 | | 21 CFR 1308.12(b)(1)(v) | |
| Halazepam | Schedule IV | Depressants | 2762 | | 21 CFR 1308.14(c)(29) | |
| Haloxazolam | Schedule IV | Depressants | 2771 | | 21 CFR 1308.14(c)(30) | |
| Heroin | Schedule I | Opium derivatives | 9200 | | 21 CFR 1308.11(c)(11) | |
| Hydrocodone | Schedule II | Substances, vegetable origin or chemical synthesis | 9193 | | 21 CFR 1308.12(b)(1)(vi) | |
| Hydromorphinol | Schedule I | Opium derivatives | 9301 | | 21 CFR 1308.11(c)(12) | |
| Hydromorphone | Schedule II | Substances, vegetable origin or chemical synthesis | 9150 | | 21 CFR 1308.12(b)(1)(vii) | |
| Hydroxypethidine | Schedule I | Opiates | 9627 | | 21 CFR 1308.11(b)(52) | |
| Ibogaine | Schedule I | Hallucinogenic substances | 7260 | | 21 CFR 1308.11(d)(21) | |
| Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide) | Schedule I | Opiates | 9827 | | 21 CFR 1308.11(b)(53) | |
| Isomethadone | Schedule II | Opiates | 9226 | | 21 CFR 1308.12(c)(10) | |
| Isotonitazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine) | Schedule I | Opiates | 9614 | | 21 CFR 1308.11(b)(54) | |
| Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) | Schedule I | Opiates | 9862 | | 21 CFR 1308.11(b)(55) | |
| Ketamine, its salts, isomers, and salts of isomers | Schedule III | Depressants | 7285 | | 21 CFR 1308.13(c)(7) | |
| Ketazolam | Schedule IV | Depressants | 2772 | | 21 CFR 1308.14(c)(31) | |
| Ketobemidone | Schedule I | Opiates | 9628 | | 21 CFR 1308.11(b)(56) | |
| Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide] | Schedule V | Depressants | 2746 | | 21 CFR 1308.15(e)(5) | |
| Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide] | Schedule V | Depressants | 2790 | | 21 CFR 1308.15(e)(6) | |
| Lemborexant | Schedule IV | Depressants | 2245 | | 21 CFR 1308.14(c)(32) | |
| Levo-alphacetylmethadol | Schedule II | Opiates | 9648 | | 21 CFR 1308.12(c)(11) | |
| Levomethorphan | Schedule II | Opiates | 9210 | | 21 CFR 1308.12(c)(12) | |
| Levomoramide | Schedule I | Opiates | 9629 | | 21 CFR 1308.11(b)(57) | |
| Levophenacylmorphan | Schedule I | Opiates | 9631 | | 21 CFR 1308.11(b)(58) | |
| Levorphanol | Schedule II | Opiates | 9220 | | 21 CFR 1308.12(c)(13) | |
| Lisdexamfetamine, its salts, isomers, and salts of its isomers | Schedule II | Stimulants | 1205 | | 21 CFR 1308.12(d)(5) | |
| Loprazolam | Schedule IV | Depressants | 2773 | | 21 CFR 1308.14(c)(33) | |
| Lorazepam | Schedule IV | Depressants | 2885 | | 21 CFR 1308.14(c)(34) | |
| Lorcaserin | Schedule IV | Lorcaserin | 1625 | | 21 CFR 1308.14(e)(1) | |
| Lormetazepam | Schedule IV | Depressants | 2774 | | 21 CFR 1308.14(c)(35) | |
| Lysergic acid | Schedule III | Depressants | 7300 | | 21 CFR 1308.13(c)(8) | |
| Lysergic acid amide | Schedule III | Depressants | 7310 | | 21 CFR 1308.13(c)(9) | |
| Lysergic acid diethylamide | Schedule I | Hallucinogenic substances | 7315 | | 21 CFR 1308.11(d)(22) | |
| Marihuana | Schedule I | Hallucinogenic substances | 7360 | | 21 CFR 1308.11(d)(23) | |
| Marihuana Extract | Schedule I | Hallucinogenic substances | 7350 | | 21 CFR 1308.11(d)(58) | |
| Marijuana | Schedule III | Hallucinogenic substances | | | 21 CFR 1308.13(g)(2) | in a U.S. Food and Drug Administration approved product or subject to a state medical marijuana license |
| Marijuana extract | Schedule III | Hallucinogenic substances | | | 21 CFR 1308.13(g)(3) | in a U.S. Food and Drug Administration approved product or subject to a state medical marijuana license |
| Mazindol | Schedule IV | Stimulants | 1605 | | 21 CFR 1308.14(f)(5) | |
| Mebutamate | Schedule IV | Depressants | 2800 | | 21 CFR 1308.14(c)(36) | |
| Mecloqualone | Schedule I | Depressants | 2572 | | 21 CFR 1308.11(e)(7) | |
| Medazepam | Schedule IV | Depressants | 2836 | | 21 CFR 1308.14(c)(37) | |
| Mefenorex | Schedule IV | Stimulants | 1580 | | 21 CFR 1308.14(f)(6) | |
| Meprobamate | Schedule IV | Depressants | 2820 | | 21 CFR 1308.14(c)(388) | |
| Mescaline | Schedule I | Hallucinogenic substances | 7381 | | 21 CFR 1308.11(d)(24) | |
| Mesocarb (N-phenyl-N ′-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate) | Schedule I | Stimulants | 1227 | | 21 CFR 1308.11(f)(9) | |
| mestanolone (17α-methyl-17β-hydroxy-5α-androstan-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(44) | |
| mesterolone (1α-methyl-17β-hydroxy-5α-androstan-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(45) | |
| meta-Fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) | Schedule I | Opiates | 9857 | | 21 CFR 1308.11(b)(59) | |
| meta-fluorofuranyl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide) | Schedule I | Opiates | 9871 | | 21 CFR 1308.11(b)(60) | |
| meta-Fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) | Schedule I | Opiates | 9858 | | 21 CFR 1308.11(b)(61) | |
| Metazocine | Schedule II | Opiates | 9240 | | 21 CFR 1308.12(c)(14) | |
| Methadone | Schedule II | Opiates | 9250 | | 21 CFR 1308.12(c)(15) | |
| Methadone-Intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane | Schedule II | Opiates | 9254 | | 21 CFR 1308.12(c)(16) | |
| Methamphetamine, its salts, isomers, and salts of its isomers | Schedule II | Stimulants | 1105 | | 21 CFR 1308.12(d)(2) | |
| methandienone (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(46) | |
| methandriol (17α-methyl-3β,17β-dihydroxyandrost-5-ene) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(47) | |
| Methaqualone | Schedule I | Depressants | 2565 | | 21 CFR 1308.11(e)(8) | |
| methasterone (2α,17α-dimethyl-5α-androstan-17β-ol-3-one or 2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(48) | |
| Methcathinone (Some other names: 2-(methylamino)-propiophenone; alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432), its salts, optical isomers and salts of optical isomers | Schedule I | Stimulants | 1237 | | 21 CFR 1308.11(f)(10) | |
| methenolone (1-methyl-17β-hydroxy-5α-androst-1-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(49) | |
| Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine) | Schedule I | Stimulants | 1478 | | 21 CFR 1308.11(f)(11) | |
| Methohexital | Schedule IV | Depressants | 2264 | | 21 CFR 1308.14(c)(39) | |
| Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) | Schedule I | Opiates | 9825 | | 21 CFR 1308.11(b)(62) | |
| methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-FUBINACA) | Schedule I | Hallucinogenic substances | 7020 | | 21 CFR 1308.11(d)(78) | |
| methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, (FUB-AMB, MMB-FUBINACA, AMB-FUBINACA) | Schedule I | Hallucinogenic substances | 7021 | | 21 CFR 1308.11(d)(79) | |
| Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methyl butanoate (other name: MMB-FUBICA) | Schedule I | Hallucinogenic substances | 7095 | | 21 CFR 1308.11(d)(114) | |
| methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (4F-MDMB-BINACA, 4F-MDMB-BUTINACA) | Schedule I | Hallucinogenic substances | 7043 | | 21 CFR 1308.11(d)(87) | |
| Methyl 2-[[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA) | Schedule I | Hallucinogenic substances | 7091 | | 21 CFR 1308.11(d)(111) | |
| methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other names: 5F-ADB; 5F-MDMB-PINACA) | Schedule I | Hallucinogenic substances | 7034 | | 21 CFR 1308.11(d)(73) | |
| methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (Other names: 5F-AMB) | Schedule I | Hallucinogenic substances | 7033 | | 21 CFR 1308.11(d)(74) | |
| methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (other names: 5F-MDMB-PICA; 5F-MDMB-2201) | Schedule I | Hallucinogenic substances | 7041 | | 21 CFR 1308.11(d)(90) | |
| methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-CHMICA, MMB-CHMINACA) | Schedule I | Hallucinogenic substances | 7042 | | 21 CFR 1308.11(d)(77) | |
| methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (Other names: MMB-CHMICA; AMB-CHMICA) | Schedule I | Hallucinogenic substances | 7044 | | 21 CFR 1308.11(d)(84) | |
| methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (other name: MDMB-4en-PINACA) | Schedule I | Hallucinogenic substances | 7090 | | 21 CFR 1308.11(d)(110) | |
| Methyl (E)-2-((1′S,6′S,7′S)-6′-ethyl-4-methoxy-3-oxo-3′,5′,6′,7′,8′,8a′-hexahydro-2′H-spiro[indoline-2,1′-indolizine]-7′-yl)-3-methoxyacrylate (commonly known as mitragynine pseudoindoxyl) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible. Since nomenclature of this substance is not internationally standardized, compounds of this structure, regardless of numerical designation of atomic positions are covered | Schedule I | Temporary listing of substances subject to emergency scheduling | 9672 | Aug. 26, 2028 | 21 CFR 1308.11(h)(89) | |
| Methyl (E)-2-((2S,3S,7aS,12aR,12bS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate (commonly known as MGM-15; also known as dihydro-7-hydroxymitragynine) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible. Since nomenclature of this substance is not internationally standardized, compounds of this structure, regardless of numerical designation of atomic positions are covered | Schedule I | Temporary listing of substances subject to emergency scheduling | 9673 | Aug. 26, 2028 | 21 CFR 1308.11(h)(90) | |
| Methyl (E)-2-((2S,3S,7aS,12aR,12bS)-3-ethyl-9-fluoro-7a-hydroxy-8- methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate (commonly known as MGM-16; also known as 9-fluoro-dihydro-7-hydroxymitragynine; or 10-fluoro-dihydro-7-hydroxymitragynine (depending on numbering convention)) including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible. Since nomenclature of this substance is not internationally standardized, compounds of this structure, regardless of numerical designation of atomic positions are covered | Schedule I | Temporary listing of substances subject to emergency scheduling | 9674 | Aug. 26, 2028 | 21 CFR 1308.11(h)(91) | |
| Methyldesorphine | Schedule I | Opium derivatives | 9302 | | 21 CFR 1308.11(c)(13) | |
| methyldienolone (17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(59) | |
| Methyldihydromorphine | Schedule I | Opium derivatives | 9304 | | 21 CFR 1308.11(c)(14) | |
| Methylphenidate | Schedule II | Stimulants | 1724 | | 21 CFR 1308.12(d)(4) | |
| Methylphenobarbital (mephobarbital) | Schedule IV | Depressants | 2250 | | 21 CFR 1308.14(c)(40) | |
| methyltestosterone (17α-methyl-17β-hydroxyandrost-4-en-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(61) | |
| methyltrienolone (17α-methyl-17β-hydroxyestra-4,9,11-trien-3-one) | Schedule III | Anabolic steroids | | | 21 CFR 1308.13(f)(62) | |
| Methyprylon | Schedule III | Depressants | 2575 | | 21 CFR 1308.13(c)(10) | |
| Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine) | Schedule I | Opiates | 9764 | | 21 CFR 1308.11(b)(67) | |